<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501254</url>
  </required_header>
  <id_info>
    <org_study_id>TROM-EC-ECC-01</org_study_id>
    <secondary_id>EudraCT number: 2004-000398-76</secondary_id>
    <nct_id>NCT00501254</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period</brief_title>
  <official_title>Randomised Clinical Trial, Parallel, Double Blind, to Evaluate the Influence of the ASA-SR (Slow-Release) in the Platelet Parameters and the Oxidative Status, in Patients With Coronary Disease of Chronic Evolution During 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm Spain</source>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacodynamic profile (antiaggregant profile, balance of prostanoids and
      nitric oxid) of a ASA-SR (slow-release)formulation in comparison with a ASA NR (normal
      release), 150 mg, during 12 months of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A large clinical trials have established the efficacy of the antiaggregant products in
           patients with ischemic cardiopathy, stroke and intermittent claudication.

        -  The acetylsalicylic acid (ASA) is the most used antiaggregant substance, nevertheless,
           and spite of being centenarian, it last some questions pending regarding the most
           appropriate dose, mechanisms of action implicated, the association with oder drugs, and
           the pharmaceutical fom in order to improve the efficacy and safety of the ASA.

        -  Some previous studies indicate that the slow release form of ASA has a different
           behaviour in the platelet effect in comparison with plain formulation.

        -  The aim of this study is to demonstrate the best antiaggregant and safety profile of a
           low dose of a slow release formulation in a long term treatment period of one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evaluation of the effect of treatment with slow release ASA on the tromboxane/prostacyclin balance and its repercusion in the platelet aggregation</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile of the two different formulations of ASA (Slow Release and Normal Release)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Cardiovascular Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Slow release acetyl salicylic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Antithrombotic effect</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous episodes of myocardial infarction

          -  Previous episodes of instable angina pectoris

          -  Previous coronary revascularization

          -  Significant arterial coronary disease

        Exclusion Criteria:

          -  Patients with other pathologies that require treatment with other antiaggregants

          -  Patients in treatment with low molecular weight heparin or oral anticoagulants

          -  Patients with antecedents of hypersensibility to ASA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloy Rueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario Virgen de la Victoria, Málaga (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Pedro de la Cruz, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Farmacología y Terapéutica Clínica Facultad de Medicina, Universidad de Málaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio González Correa, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Farmacología y Terapéutica Clínica Facultad de Medicina, Universidad de Málaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2007</study_first_submitted>
  <study_first_submitted_qc>July 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2007</study_first_posted>
  <last_update_submitted>July 17, 2007</last_update_submitted>
  <last_update_submitted_qc>July 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2007</last_update_posted>
  <keyword>Slow release ASA</keyword>
  <keyword>Platelet functionalism</keyword>
  <keyword>Secondary cardiovascular prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylic Acid</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

